China is first country to approve Roche’s C5 inhibitor crovalimab, a subcutaneous option for patients with rare disease PNH.

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...